AAM
PBYI icon

Aberdeen Asset Management’s Puma Biotechnology PBYI Stock Holding History

Aberdeen Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-36,220
Closed -$1.08M – 743
2016
Q2 		$1.08M Sell
36,220
-720
-2% -$22.5K ﹤0.01% 624
2016
Q1 		$1.08M Buy
36,940
+3,695
+11% +$167K ﹤0.01% 621
2015
Q4 		$2.85M Buy
33,245
+781
+2% +$61.3K 0.01% 518
2015
Q3 		$2.45M Buy
+32,464
New +$3.07M 0.01% 486

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Aberdeen Asset Management's PBYI Position: Q3 2016 in Review

Aberdeen Asset Management sold out of Puma Biotechnology (PBYI) in Q3 2016, closing a stake of 36,220 shares — an estimated $1.08M sold.

Aberdeen Asset Management first reported a position in PBYI in Q3 2015 and held it in 4 quarters. The position peaked at $2.85M in Q4 2015. 149 funds tracked by Wall St. Rank hold PBYI as of Q3 2016.

  • Aberdeen Asset Management reported no remaining Puma Biotechnology position as of Q3 2016 after selling out during the quarter.
  • Aberdeen Asset Management sold 36,220 Puma Biotechnology shares in Q3 2016, an estimated $1.08M.
  • Aberdeen Asset Management first reported a position in Puma Biotechnology in Q3 2015 and held it in 4 quarters.
  • Aberdeen Asset Management's Puma Biotechnology position peaked at $2.85M in Q4 2015.
  • 149 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2016.

Based on Aberdeen Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.